These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 22681779

  • 1. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD, Mohammed Z, Bacani JT, Lai R, Ingham RJ.
    BMC Cancer; 2012 Jun 08; 12():229. PubMed ID: 22681779
    [Abstract] [Full Text] [Related]

  • 2. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD, Lee JK, Bacani JT, Lai R, Ingham RJ.
    Int J Clin Exp Pathol; 2011 Jan 30; 4(2):124-33. PubMed ID: 21326808
    [Abstract] [Full Text] [Related]

  • 3. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
    Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G.
    Blood; 2007 Nov 01; 110(9):3374-83. PubMed ID: 17690253
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J, Yin M, Zhu Y, Gu L, Zhang Y, Li Q, Jia C, Ma Z.
    BMC Cancer; 2013 Oct 10; 13():471. PubMed ID: 24112608
    [Abstract] [Full Text] [Related]

  • 5. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT, Zhao C, Zhang Q, Wasik MA.
    Blood; 2017 Feb 16; 129(7):823-831. PubMed ID: 27879258
    [Abstract] [Full Text] [Related]

  • 6. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O, Samadi N, Wu C, Lavasanifar A, Lai R.
    Leuk Lymphoma; 2016 May 16; 57(5):1154-62. PubMed ID: 26133723
    [Abstract] [Full Text] [Related]

  • 7. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

  • 8. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, Kneteman NM, Lai R.
    Blood; 2015 Jul 16; 126(3):336-45. PubMed ID: 25921060
    [Abstract] [Full Text] [Related]

  • 9. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.
    Exp Hematol; 2006 Dec 16; 34(12):1670-9. PubMed ID: 17157164
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak LW, Ford RJ, Amin HM.
    Blood; 2009 Jul 09; 114(2):360-70. PubMed ID: 19423729
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R.
    J Biol Chem; 2010 Aug 20; 285(34):26441-50. PubMed ID: 20554525
    [Abstract] [Full Text] [Related]

  • 15. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
    Wu F, Wang P, Zhang J, Young LC, Lai R, Li L.
    Mol Cell Proteomics; 2010 Jul 20; 9(7):1616-32. PubMed ID: 20393185
    [Abstract] [Full Text] [Related]

  • 16. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
    Babin L, Darchen A, Robert E, Aid Z, Borry R, Soudais C, Piganeau M, De Cian A, Giovannangeli C, Bawa O, Rigaud C, Scoazec JY, Couronné L, Veleanu L, Cieslak A, Asnafi V, Sibon D, Lamant L, Meggetto F, Mercher T, Brunet E.
    Mol Cancer; 2022 Mar 04; 21(1):65. PubMed ID: 35246138
    [Abstract] [Full Text] [Related]

  • 17. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
    Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B.
    Blood; 2004 Feb 15; 103(4):1464-71. PubMed ID: 14563642
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K.
    J Cancer Res Clin Oncol; 2014 Apr 15; 140(4):589-98. PubMed ID: 24509625
    [Abstract] [Full Text] [Related]

  • 20. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
    Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX.
    Leukemia; 2015 Nov 15; 29(11):2162-72. PubMed ID: 25987255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.